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In South Africa (SA), as in most African countries, sexually 
transmitted infections (STIs) are managed using the syndromic 
approach.[1] This approach was adapted from the World Health 
Organization (WHO) guidelines as a core intervention for STI 
management. It is based on treating multiple causes or aetiological 
factors associated with common genital symptoms, rather than a 
specific laboratory-confirmed causative pathogen.[2] It allows for 
treatment to be prescribed on the same day without waiting for 
confirmatory laboratory results.[3] It also includes some general 
measures to reduce the risk of STI, such as risk-reduction counselling, 
partner notification, HIV counselling and testing, and condom and 
circumcision promotion.[3] The main limitation of this approach is 
that the treatment algorithms have poor specificity for STI pathogens, 
leading to inappropriate use of antimicrobials, particularly for non-
STI repeat genital symptoms.[4-7] The consequences are persistence or 
non-resolution of genital symptoms, leading to repeat clinic visits for 
the same symptoms. 
In SA, the National Institute for Communicable Diseases (NICD), 
through the Group for Enteric Respiratory and Meningeal disease 
Surveillance in South Africa (GERMS-SA), has since 2005 conducted 
microbiological surveillance of STIs at selected sentinel sites, in line 
with WHO recommendations. The microbiological surveillance 
programme monitors the prevalence of pathogens associated with the 
three main STI syndromes, i.e. vaginal discharge syndrome (VDS), 
male urethral syndrome (MUS) and genital ulcer syndrome (GUS). 
The programme also monitors Neisseria gonorrhoeae antimicrobial 
drug-resistance profiles over time. These data are used to validate 
and update the syndromic management guidelines used at primary 
healthcare facilities across the country.
The current primary healthcare standard treatment guidelines 
for STI management in SA do not prescribe specific indications 
for microbiological testing for patients with or without repeat 
STI symptoms.[3] Consequently, there is a lack of impetus among 
clinicians to conduct laboratory tests to identify specific pathogens. 
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Background. South African guidelines recommend a syndromic approach for the management of sexually transmitted infections (STIs), 
based on the presence of genital symptoms. However, the guidelines do not prescribe specific indications for microbiology testing for 
patients presenting with or without repeat genital symptoms. 
Objectives. To describe the prevalence of and factors associated with repeat genital symptoms among STI service attendees at primary 
care facilities. 
Methods. This was a cross-sectional study at 7 STI primary care facilities participating in the aetiological surveillance of STIs between 
January 2015 and December 2016. Demographic and clinical information and appropriate genital specimens were collected from 
participants presenting with vaginal discharge syndrome (VDS), male urethral syndrome (MUS) and/or genital ulcer syndrome (GUS). 
Repeat genital symptoms were defined as self-reported history of the same STI-related genital symptoms in the preceding 12 months. 
Multivariable logistic regression identified factors associated with repeat genital symptoms.
Results. Of 1 822 eligible participants, 480 (30%) had repeat genital symptoms (25% and 75% in the preceding 3 months and 12 months, 
respectively). Of those with repeat genital symptoms, the median age was 28 (interquartile range (IQR) 24 - 32) years, and 54% were females. 
The most common aetiological agents among participants with VDS, MUS and GUS were bacterial vaginosis (n=132; 55%), Neisseria 
gonorrhoeae (n=172; 81%) and ulcers (n=67; 63%), respectively. One hundred and seven (20%) participants had no detectable common STI 
aetiology. In the multivariable analysis, repeat genital symptoms were associated with HIV co-infection (adjusted odds ratio (aOR) 1.43; 
95% confidence interval (CI) 1.14 - 1.78), VDS diagnosis (aOR 1.39; 95% CI 1.10 - 1.76), self-reported condom use (aOR 1.56; 95% CI 1.20 - 
2.03) and age 25 - 34 years (aOR 1.33; 95% CI 1.03 - 1.71). 
Conclusions. Our study found a high prevalence of repeat genital symptoms ‒ a significant proportion without STI aetiology. Identified 
factors of repeat genital symptoms highlight the need for improved integration of HIV and STI prevention and management. Further 
research is needed to determine the aetiology of repeat genital symptoms and the contribution of non-STI causes.
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Furthermore, there is a paucity of literature on the most common 
aetiological agents of genital symptoms to inform evidence-based 
decisions for healthcare workers, e.g. nurses in primary care clinics. 
The management of STIs is further complicated by the lack of a 
sufficient number of clinicians who are specifically trained for 
this role.[8] This predominantly affects the success of the syndromic 
approach, as healthcare workers need to have knowledge of the aetiology, 
epidemiology and antimicrobial susceptibility patterns of STIs.[9] 
Objectives
The objective of this study was to determine the prevalence of repeat 
genital symptoms, and to identify associated pathogens and related 
factors among STI service attendees enrolled at primary care clinic 
sentinel surveillance sites in 5 provinces of SA.
Methods
Study design
We conducted a cross-sectional study using secondary data collected 
from STI microbiological sentinel surveillance sites from Jan uary 2015 
to December 2016.
Study population and setting 
From January 2015 to December 2016, the STI microbiological 
surveillance programme conducted sentinel surveillance at 7 sites 
in 5 provinces, including Gauteng (1 site), Mpumalanga (2 sites), 
KwaZulu-Natal (2 sites), Eastern Cape (1 site) and North West (1 site). 
Six of the 7 sentinel sites were primary healthcare clinics located in 
urban areas, and 1 primary healthcare facility in Mpumalanga was in 
a rural area. The surveillance enrolled participants aged ≥18 years, 
who presented with symptoms consistent with ≥1 of the 3 main STI 
syndromes, including VDS, MUS and/or GUS, from January 2015 
to December 2016. The sites were chosen by purposive sampling of 
facilities that met predetermined criteria, including high caseload 
of MUS in the preceding year, willingness of province and district 
offices to grant approval, availability of resources, such as treatment, 
office space for surveillance nurses and willingness of local staff to 
participate in surveillance activities. 
Data collection 
Consecutive participants presenting with symptoms consistent with 
MUS, VDS or GUS at the sentinel sites were invited to participate in 
the survey conducted by trained professional nurses. The surveillance 
nurses assessed eligibility of each individual and thereafter obtained 
written informed consent. Information obtained from the survey 
included demographic data, as well as clinical and sexual history. 
Personal identifiers were not collected. The information included: 
(i) individual demographic characteristics (age, gender, ethnic group, 
self-reported sexual orientation); (ii) clinical information (diagnosis 
of VDS, MUS and/or GUS on the day of enrolment, past history 
of treatment for the same STI syndrome in the past 3 months, past 
history of treatment for the same or different STI syndrome in the 
past 12 months); and (iii) sexual behavioural history (condom use 
with last sexual encounter, age at sexual debut, sexual intercourse with 
someone living in another province and/or someone living outside 
SA in the preceding 3 months). The completed case investigation 
forms were couriered to the Centre for HIV and STI (CHIVSTI), 
National Institute for Communicable Diseases (NICD), and captured 
into a password-protected database that is stored on a server. 
Specimen collection
For men with MUS, an endo-urethral swab was taken from each 
individual, placed in a plastic tube for multiplex polymerase chain 
reaction (M-PCR) testing at the CHIVSTI at NICD. For women with 
VDS, a swab was collected from the lateral vaginal wall and posterior 
fornix, followed by a smear made on a glass microscope slide. An 
endocervical swab was subsequently taken for M-PCR testing and 
handled similarly to the M-PCR swab from MUS participants. Men 
and women with genital ulceration had 2 swabs taken from the lesion. 
The first ulcer swab was smeared on a microscope slide and the second 
was placed in a plastic tube for subsequent M-PCR testing. Lastly, 10 mL of 
blood was drawn from consenting participants for HIV testing. 
Laboratory testing
All specimens collected at sentinel sites were transported to the 
CHIVSTI reference laboratory for processing and storage. A Gram 
stain was used to detect bacterial vaginosis and candidiasis on vaginal 
smears. An in-house real-time M-PCR assay for STI discharge 
pathogens was used for the detection of N. gonorrhoeae, Chlamydia 
trachomatis, Mycoplasma genitalium and Trichomonas vaginalis. 
M-PCR was also used to detect Haemophilus ducreyi, Treponema 
pallidum, C. trachomatis and herpes simplex virus (HSV) in DNA 
extracted from the ulcer swabs. If C. trachomatis was detected, an 
additional real-time in-house PCR assay was used to determine 
the presence of serovars L1 - L3, which cause lymphogranuloma 
venereum (LGV), with associated genital ulceration. If HSV was 
detected, a commercial PCR assay (Sacace Biotechnologies, Italy) 
was done to further categorise samples into subtypes HSV-1 and 
HSV-2. Serum specimens were screened for HIV using two rapid 
immunochromatographic assays to confirm the first positive results 
(Unigold, Ireland; Determine, Japan).
Case definition 
For the purpose of this study, we defined repeat genital symptoms as 
the self-reported history of treatment for the same genital symptoms 
in the preceding 12 months. 
Data management and statistical analysis 
Demographic, clinical and laboratory data stored on the database 
were exported into Stata 14 (Stata Corp., USA) for all statistical 
analyses. Descriptive statistics were used to report characteristics 
of STI service attendees. Proportions were compared between 
participants with repeat genital symptoms and those without using 
the χ2 or Fisher’s exact test, where appropriate. The prevalence 
was calculated by dividing the number of all participants who met 
the criteria for repeat genital symptoms by the total number of all 
STI service attendees enrolled, and corresponding 95% confidence 
intervals (CIs) were calculated. Multivariable logistic regression was 
used to identify factors associated with repeat genital symptoms. A 
manual forward stepwise approach was used to identify statistically 
significant factors. A cut-off p-value of 0.2 in the bivariate analyses 
was used to include variables in the multivariable model. A p-value 
of ≤0.05 in the multivariable model was considered statistically 
significant. Multicollinearity tests were performed before entering 
variables in the multivariable model to ensure that only non-collinear 
variables were included. 
Ethical approval
Ethical approval for ongoing activity of GERMS-SA surveillance was 
received from the Human Research Ethics Committee (Medical), 
University of the Witwatersrand, Johannesburg (ref. no. M081117). 
Ethical clearance and approval for this study was further obtained 
from the Faculty of Health Sciences Research Ethics Committee, 
University of Pretoria (ref. no. 388/2016), and from the CHIVSTI at 
the NICD. 
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Results
Description of patients enrolled
A total of 1 824 participants were enrolled during the study period. 
Of these, 1 822 (99%) participants were included in the analysis. Two 
participants who were <18 years old were excluded. Of the 1 822 eligible 
participants, the prevalence of repeat genital symptoms was 30.0% 
(n=546) (95% CI 27.9 - 32.1). Among these, 138 (24.5%) and 408 
(74.7%) reported repeat genital symptoms in the preceding 3 and 
12 months prior to enrolment, respectively.
Demographic and clinical characteristics of patients 
with repeat genital symptoms
Of the 546 participants with repeat genital symptoms, the median age 
was 28 (interquartile range (IQR) 24 - 32) years, with the majority 
(57.6%) in the age group 25 - 34 years (Table 1). Most participants 
(n=173; 31.7%) were enrolled at KwaZulu-Natal sentinel sites, 
followed by participants at the Gauteng site (n=158; 28.9%). The 
Eastern Cape site had the lowest number of participants (n=39; 
7.1%). Participants with repeat genital symptoms were more likely to 
be HIV co-infected (46.9% v. 35.0%; p=0.002), and diagnosed with 
VDS (44.5% v. 35.3%; p=0.001).
Prevalence of sexually transmitted infection aetiology in 
participants with repeat genital symptoms
Among participants with repeat genital symptoms and VDS, bacterial 
vaginosis (n=132; 55%) was the most common aetiology identified, 
followed by Candida infection (n=55; 23%). M. genitalium infection 
(n=21; 9%) was the least common aetiological agent detected (Fig. 1). 
Aetiological agents (>1) were detected in 36 (14%) participants, while 
none was detected in 53 (20%) participants. 
Among participants with repeat genital symptoms and MUS, 
N. gonorrhoeae (n=172; 81%) and C. trachomatis infections (n=54; 
25%) were the most common aetiological agents. M. genitalium 
(n=11; 5%) and T. vaginalis (n=8; 4%) were the least common aetiological 
agents (Fig. 1). Furthermore, aetiological agents (>1) were detected in 51 
(24%) participants, while none was detected in 21 (10%) participants. 
Among 107 participants with repeat genital symptoms and GUS, 67 
(63%) had ulcers associated with HSV-2, and 8 (7%) with T. pallidum 
(Fig. 1). Donovanosis, lymphogranuloma venereum and H. ducreyi 
were not detected. The most common aetiological agent was HSV-2 
and the least common cause was HSV-1 (Fig. 1). Mixed aetiological 
agents were identified in 2 (2%) and none was identified in 33 (31%) 
participants. Overall, there were no significant differences in the 
relative prevalence of aetiological pathogens in the three syndromes 
(VDS, MUS and GUS).
Factors associated with repeat genital symptoms
In the univariable analysis, repeat genital symptoms were associated 
with age (25 - 34 years) (odds ratio (OR) 1.34; 95% CI 1.05 - 1.71), 
enrolment at the KwaZulu-Natal (OR 2.62; 95% CI 2.02 - 3.43), Eastern 
Cape (OR 2.75; 95% CI 1.73 - 4.33) and North West (OR 1.44; 
95% CI 1.02 - 2.03) sites, HIV co-infection (OR 1.64; 95% CI 1.34 - 
Table 1. Description of participants with/without repeat genital symptoms in 5 provinces, South Africa, January 2015 - 
December 2016
Characteristics Total (N=1 822), n (%)
With repeat genital 
symptoms (n=546), n (%)
Without repeat genital 
symptoms (n=1 276), n (%) p-value
Age, years
18 - 24 491 (27.2) 128 (23.6) 363 (28.7)
25 - 34 977 (54.1) 314 (57.9) 663 (52.5) 0.116
35 - 44 259 (14.3) 80 (14.8) 179 (14.2)
45 - 54 57 (3.2) 16 (3.0) 41 (3.2)
≥55 22 (1.2) 4 (0.7) 18 (1.4)
Gender
Female 961 (52.7) 295 (54.0) 566 (44.4) <0.001
Male 861 (47.3) 251 (46.0) 710 (55.6)
Province
Mpumalanga 414 (22.7) 112 (20.5) 302 (23.7)
KwaZulu-Natal 400 (22.0) 173 (31.7) 227 (17.8) <0.001
Gauteng 703 (38.6) 158 (28.9) 545 (42.7)
Eastern Cape 88 (4.8) 39 (7.2) 49 (3.8)
North West 217 (11.9) 64 (11.7) 153 (12.0)
Ethnicity
Black African 1 811 (99.4) 540 (98.9) 1 271 (99.6) 0.122
Other 9 (0.6) 6 (1.1) 5 (0.4)
Sexual orientation
Heterosexual 1 801 (98.9) 540 (98.9) 1 261 (98.8) 0.837
Homosexual 21 (1.1) 6 (1.1) 15 (1.2)
Clinical syndrome at enrolment
VDS 694 (38.1) 243 (44.5) 451 (35.3) 0.001
MUS 762 (41.8) 196 (35.9) 566 (44.4)
GUS 366 (20.1) 107 (19.6) 259 (20.3)
HIV status
Positive 703 (38.6) 256 (46.9) 447 (35.0) 0.002
VDS = vaginal discharge syndrome; MUS = male urethral syndrome; GUS = genital ulcer syndrome.
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2.01), self-reported condom use during the last sexual encounter 
(OR 1.52; 95% CI 1.18 - 1.96) and VDS diagnosis (OR 1.48; 95% CI 
1.19 - 1.85) (Table 2). Participants with a sexual partner in another 
country had decreased odds of repeat genital symptoms (OR 0.70; 
95% CI 0.50 - 0.98).
In the multivariable analysis, repeat genital symptoms were 
independently associated with self-reported condom use at last 
sexual encounter (adjusted odds ratio (aOR) 1.56; 95% CI 1.20 - 
2.02; p=0.001), HIV co-infection (aOR 1.42; 95% CI 1.14 - 1.78; 
p=0.002), age 25 - 34 years (aOR 1.33; 95% CI 1.03 - 1.71; p=0.028) 
and VDS diagnosis (aOR 1.39; 95% CI 1.10 - 1.76; p=0.006) (Table 2). 
Compared with those in Gauteng, participants from KwaZulu-Natal 
(aOR 2.38; 95% CI 1.79 - 3.16; p<0.001) and the Eastern Cape 
(aOR 2.96; 95% CI 1.85 - 4.75; p<0.001) were more likely to have 
repeat genital symptoms. Because most women had VDS, and MUS 
cases are generally males, we did not include gender in the model to 
avoid collinearity, as these variables are correlated. 
Discussion 
Our study found a high prevalence of repeat genital symptoms among 
participants presenting for STI services at primary care facilities, 
with a significant proportion having no detectable STI aetiology. 
The most prevalent STI aetiological agents were bacterial vaginosis, 
N. gonorrhoeae and HSV-2 among participants with VDS, MUS and 
GUS, respectively. Repeat genital symptoms were independently 
associated with a diagnosis of VDS at enrolment, HIV co-infection, 
self-reported condom use at last sexual encounter and age between 
25 and 34 years.
The burden of repeat genital symptoms was significantly higher 
than the 12% reported in a study among Kenyan patients attending 
an STI clinic.[10] This difference between the two studies was probably 
due to the differences in the definition of repeat genital symptoms 
or the population under surveillance. We found that, although 
the prevalence of repeat genital symptoms was high, a significant 
proportion of participants had no detectable STI aetiology. Moreover, 
a study done in our STI microbiological surveillance on resistance 
of STI pathogens showed no evidence of N. gonorrhoeae resistance 
to the currently used dual treatment regimen.[11] Therefore, it is 
unlikely that the repeat genital symptoms in our study were due 
to treatment failure because of antibiotic resistance. The similar 
distribution of aetiological agents among those with repeat genital 
symptoms suggests that re-infection, persistent or recurrent infection 
due to suboptimal treatment, or non-STI causes that remain 
untreated after initial presentation, could have been important 
factors in our population. Further research studies are required to 
properly determine the aetiology of repeat genital symptoms and the 
contribution of non-STI causes. 
Understanding the factors that predispose participants to repeat 
genital symptoms is necessary to improve the management of 
STIs. We identified a number of factors that place participants at 
increased risk of repeat genital symptoms, including VDS diagnosis. 
Women may be more vulnerable to repeat genital symptoms from 
STI infections due to their anatomical and physiological structure 
(genitalia), which is more susceptible to infection than that of men.[6,7,12] 
Furthermore, women may have less power to negotiate safer sex, 
and as a result they are more likely to be re-infected.[6,7,13] Studies 
also suggest that women with STI symptoms are more likely to 
seek medical treatment than their male counterparts.[13] Therefore, 
it is less probable that partners are treated, thereby resulting in 
repeat infections. Although partner notification and treatment 
are components of STI management in our standard treatment 
guidelines, it is poorly implemented in SA.[14] 
Another concern in our study was the association of HIV with 
repeat genital symptoms, the relatively high HIV seropositivity rate 
of 47% among participants who reported repeat genital symptoms, 
as well as the high overall HIV seropositivity rate in the entire study 
population (~39%). These findings may be biologically plausible, 
given that the presence of STIs increases the likelihood of HIV 
acquisition and transmission.[6,7,12,15,16] Furthermore, STIs that cause 
ulcers or inflammation significantly increase vulnerability to HIV 
infection.[12,16,17] It is also known that HIV can modify the clinical 
progression of some STIs, especially among immunosuppressed 
participants.[17,18] This probably explains why there was also a high 

















BV     CA    NG     CT     TV    MG    MA    NA NG     CT     TV    MG    MA    NA HSV-2    TP   HSV-1  NU   MU
VDS                                                                                   MUS                                                                  GUS
Repeat symptoms  Non-repeat symptoms
Fig. 1. Comparison of prevalence of sexually transmitted infection (STI) syndrome aetiological agents in recurrent and non-recurrent cases in South Africa 
(microbiological STI surveillance system, 2015 - 2016). (BV = bacterial vaginosis; CA = candidiasis; NG = Neisseria gonorrhoeae; CT = Chlamydia 
trachomatis; TV = Trichomonas vaginalis; MG = Mycoplasma genitalium; MA = multiple aetiologies; NA = no aetiologies; HSV-2 = herpes simplex virus 
type 2; TP = Treponema pallidum; HSV-1= herpes simplex virus type 1; NU = no ulceration; MU = mixed ulcerations; VDS = vaginal discharge syndrome; 
MUS = male urethral syndrome; GUS = genital ulcer syndrome.)
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Of note was the association of repeat genital symptoms in the age 
category 25 - 34 years and self-reported condom use at last sexual 
encounter. The association of repeat genital symptoms between 
25 and 34 years of age was not unexpected. The HIV prevalence is 
similarly high in this age group, which suggests unsafe sexual practices 
that may predispose to repeat genital symptoms. The self-reported 
recent condom use in our study may be an individual’s response to 
the presence of genital symptoms and taking precautionary measures 
to prevent potential spread to a sexual partner. Other studies found 
that participants who perceived themselves to be at high risk of STIs 
were more likely to use condoms than those with a perceived low risk 
of STIs.[18-20] Repeat infection may be due to other STI causes, which 
condom use may not fully prevent, such as herpes and syphilis.[21] 
Unfortunately, our data did not permit us to evaluate the extent of or 
consistency in condom use during last sexual encounter. 
Study limitations
This study had some limitations. Our study population comprised 
patients enrolled for microbiological surveillance; therefore, our 
findings may not be generalisable to the wider population of SA. 
Moreover, the data did not incorporate other potentially explanatory 
factors, such as number of sexual partners, partner notification, 
treatment history, knowledge of HIV status or antiretroviral treatment 
use, and frequency or duration of previous or current genital 
symptoms. The associations between repeat genital symptoms and 
some factors, e.g. HIV infection, could not be assessed conclusively 
because of the cross-sectional nature of the study. Information 
bias may have been introduced by the subjective ascertainment 
of using self-reported data of repeat genital symptoms and sexual 
behaviour. Therefore, the information may be subject to bias and/or 
misclassification. 
Conclusions
Despite these limitations, our study found a high prevalence of repeat 
genital symptoms ‒ a significant proportion without STIs, which 
are commonly identified as aetiological agents. The association of 
HIV infection with repeat genital symptoms highlights the need for 
improved integration of HIV and STI prevention and management. 
Further research studies are needed to properly determine the aetiology 
of repeat genital symptoms and the contribution of non-STI causes.





crude OR (95% CI) p-value
Multivariable 
analysis, adjusted 
OR (95% CI) p-value
Age, years
18 - 24 491 128 (26.1) Reference
25 - 34 977 314 (32.1) 1.34 (1.05 - 0.71) 0.017 1.33 (1.03 - 1.71) 0.028
35 - 44 259 80 (30.9) 1.27 (0.91 - 1.77) 0.265 1.13 (0.80 - 1.60) 0.487
45 - 54 57 16 (28.1) 1.11 (0.60 - 2.04) 0.745 0.82 (0.44 - 1.56) 0.552
≥55 22 4 (18.2) 0.63 (0.21 - 1.90) 0.412 0.55 (0.180 - 1.70) 0.300
Province
Gauteng 703 58 (22.5) Reference
KwaZulu-Natal 400 173 (43.3) 2.63 (2.02 - 3.43) <0.001 2.96 (1.79 - 3.16) <0.001
Mpumalanga 414 112 (27.1) 1.28 (0.97 - 1.69) 0.085 1.23 (0.92 - 1.64) 0.154
Eastern Cape 88 39 (44.3) 2.75 (1.73 - 4.33) <0.001 2.96 (1.85 - 4.75) <0.001
North West 217 64 (29.5) 1.44 (1.03 - 2.03) 0.035 1.34 (0.94 - 1.91) 0.110
Having a sexual partner in another 
province
No 1 530 465 (30.4) Reference
Yes 292 81 (27.7) 0.87 (0.67 - 1.16) 0.365
Having a sexual partner outside SA
No 1 608 495 (30.8) Reference
Yes 214 51 (23.8) 0.70 (0.50 - 0.98) 0.038 0.92 (0.64 - 0.30) 0.624
Age at first sex debut, years
<17 652 198 (30.4) Reference
≥17 1 079 321 (29.8) 0.97 (0.79 - 1.20) 0.786    
HIV status
Negative 1 119 290 (25.9) Reference
Positive 703 256 (36.4) 1.64 (1.34 - 2.01) <0.001 1.43 (1.14 - 1.78) 0.002
Self-reported condom use
No 1 500 425 (28.3) Reference
Yes 322 121 (37.6) 1.52 (1.18 - 1.96) 0.001 1.56 (1.20 - 2.03) 0.001
STI syndrome diagnosis
MUS 762 196 (35.9) Reference
VDS 694 243 (44.5) 1.48 (1.19 - 1.85) <0.001 1.39 (1.10 - 1.76) 0.006
GUS 366 107 (19.6) 1.14 (0.85 - 1.52) 0.380 1.16 (0.85 - 1.58) 0.353
OR = odds ratio; CI = confidence interval; SA = South Africa; STI = sexually transmitted infection; MUS = male urethral syndrome; VDS = vaginal discharge syndrome;  
GUS = genital urethral syndrome.
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